Medplus Health Serv.

MedPlus Health Services scheduled a board meeting for November 6 to consider a buyback of its fully paid-up equity shares. The proposal was to be considered under Sections 68, 69 and 70 of the Companies Act and the SEBI buy-back regulations. The trading window for designated persons closed on October 30 until 48 hours after the outcome was made public. The company operated 5,642 stores at the end of September across 13 states and one union territory, and pharmacy retail accounted for about 98% of consolidated revenue. Consolidated revenue was about Rs 6,892 crore in the year to March, while second-quarter revenue was Rs 2,037.1 crore with operating EBITDA of Rs 98.1 crore. Cash and investments stood at Rs 543.9 crore at the end of September.

Powered by Tijori

Catalyst Trusteeship took pledge over an additional 34 lakh equity shares of Medplus Health Services, representing 2.83% of equity capital, on 29 September and 23 October 2026. Its encumbered holding rose to 2.41 crore shares, or 20.10% of capital, from 2.07 crore shares. Lone Furrow had added 16 lakh shares on 29 September and Agilemed added 5.5 lakh shares on 30 September to maintain 2.10 times security cover with no fresh borrowing. Total promoter encumbrance stood at 3.58 crore shares, equal to 74.10% of promoter holding. Medplus operated 5,642 pharmacy stores across 13 states and a union territory in September and reported consolidated revenue of about Rs 6,892 crore in FY26.

Powered by Tijori

Agilemed Investments, a promoter of Medplus Health Services, created pledges over an additional 550,000 shares on September 30, 2026, to maintain required security cover on existing non-convertible debentures. The pledge covered 300,000 shares linked to Modulus Alternatives Investment Managers and 250,000 shares linked to Neo debenture holders, with no fresh borrowing undertaken. Agilemed’s encumbered holding rose to 13.43 million shares, or 11.18% of Medplus’s share capital. Total promoter encumbrance reached 35.78 million shares, roughly 74% of promoter holdings and about 30% of Medplus’s equity. A 5 lakh-share top-up in August had taken promoter encumbrance to 69.65% of promoter holdings. Medplus’s consolidated revenue was about ₹6,892 crore in FY26, with pharmacy retail accounting for roughly 98% of revenue.

Powered by Tijori

Agilemed Investments Private Limited pledged 62.51 lakh equity shares of MedPlus Health Services, representing 5.20% of its voting capital, in favour of Catalyst Trusteeship as debenture trustee for debenture holders. The encumbrance comprised 48.51 lakh shares pledged on December 16, 2025, 9 lakh on July 24, 2026 and 5 lakh on August 19, 2026. MedPlus had equity share capital of 12.01 crore shares and diluted share capital of 12.02 crore shares. Promoter pledge stood at 60.7% of promoter holdings, after a December 2025 pledge creation had taken the level to 69.4%. Revenue was ₹68,924m in FY26, with pharmacy retail accounting for about 98% of revenue.

Powered by Tijori

Medplus Health Services' promoter Lone Furrow Investments created an additional pledge of 29 lakh equity shares on July 24, 2026, in favour of debenture trustee Catalyst Trusteeship Limited, to restore the security cover ratio under an existing share pledge agreement. The new pledge raised Lone Furrow’s total encumbered holding to 54 lakh shares and lifted the overall promoter encumbrance to 68.62 per cent of promoter shareholding. Promoter pledging has been a recurring feature at Medplus; an earlier spike to 69.4 per cent in December 2025 was followed by a partial release that brought the ratio back to 60.7 per cent. Medplus operates the country’s second-largest pharmacy retail chain, with revenue of Rs 68,924 million in FY26 and a net cash balance sheet.

Powered by Tijori

Lone Furrow Investments Private Limited, a promoter of Medplus Health Services, pledged an additional 29,00,000 equity shares on 24 July 2026 to restore the security cover ratio on an existing ₹550 crore non-convertible debenture facility. The top-up lifted Lone Furrow's total encumbered shares to 54,00,000, or 4.49 per cent of the company's equity, while combined promoter encumbrance stood at 68.62 per cent of promoter shareholding. Promoter encumbrance had briefly touched 69.4 per cent in December 2025 before declining to 60.7 per cent by end-December following a partial release of pledged shares. Medplus Health Services reported revenue of ₹18,796 million for the June 2026 quarter, a 22 per cent year-on-year increase, while operating margins contracted to 3.5 per cent. The debenture facility, originally issued by Dureleg Manufacturing and now assumed by Lone Furrow through a scheme of amalgamation, carries a security cover ratio of 2.10 times.

Powered by Tijori

MedPlus Health Services suspended two capital expenditure projects that its board had approved just two days earlier, citing a reassessment of business conditions and the market outlook. The shelved plans included a food park being set up by a material subsidiary, Optical Health Solutions, and a concierge health and wellness facility in Hyderabad. The board took the decision on 23 July after a review of the company's structure, though it said the move would not affect existing operations or business performance.

Powered by Tijori

July 23 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - KEEPS FOOD PARK AND CONCIERGE HEALTH FACILITY CAPEX IN ABEYANCE

• MEDPLUS HEALTH SERVICES - KEEPS CAPEX PLANS APPROVED ON JULY 21 IN ABEYANCE

Source text: ID:nBSE1XyJLY

Further company coverage: MEDP.NS

(([email protected];))

** India's Medplus Health Services MEDP.NS slumps 15.4% to nearly 18-month low of 676 rupees

** Set for biggest daily pct drop since listing in December 2021

** Pharmacy retail-chain operator reports 22% plunge in first-quarter net profit, hurt by rising competition and increasing costs due to an aggressive store expansion strategy

** Nomura says gross profit growth at 14% year-on-year was slowest in four years, with gross margin down 163 basis points

** Attributes weak quarter to lower contribution from pharma private label and higher overhead expenses

** More than 560,000 shares change hands, ~3.6x of 30-day average daily volume

** Stock rated "buy" on average by 7 brokerage firms, median PT at 1,150 rupees, per data compiled by LSEG

** YTD, MEDP down 16.3%

(Reporting by Vivek Kumar M)

(([email protected];))

July 21 (Reuters) - Indian Pharmacy retail-chain operator MedPlus Health Services MEDP.NS on Tuesday reported an about 22% plunge in first-quarter net profit, hurt by rising competition and increasing costs due to an aggressive store expansion strategy.

• The company reported a consolidated net profit of 331.8 million rupees ($3.45 million) for the three months ended June 30, down from 423.6 million rupees a year earlier

• Costs associated with expansion for India's second-largest pharmacy retailer in terms of number of stores operated, crimped margins

• Analysts had noted that the company's store expansion and rising adoption of diabetes and obesity treatments are expected to drive long-term growth in India's organised pharmacy retail

• MedPlus reported a 21.8% increase in quarterly revenue to 18.8 billion rupees, helped by a 22% growth in retail sales

• Its Optival Health Solutions unit approved a 400 million rupees capex for a food Park with a cold-press oil extraction unit. It also plans a 1.15 billion investment for a subscription-based concierge health and wellness services facility

• MedPlus, which competes with unlisted peers such as Tata 1mg, Apollo Pharmacy and Reliance Retail's Netmeds, has plans to open 800 stores this financial year.

($1 = 96.2350 Indian rupees)

(Reporting by Saikeerthi in Bengaluru and Urvi Dugar; Editing by Joyjeet Das)

(([email protected]; (+91) 8296756080))

July 1 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - OPTIVAL HEALTH SOLUTIONS RECEIVES SUSPENSION ORDER FOR DRUG LICENSE OF STORE IN KARNATAKA

Source text: ID:nBSE7sPV0m

Further company coverage: MEDP.NS

(([email protected];))

June 26 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT OPTIVAL HEALTH SOLUTIONS RECEIVES THREE DRUG LICENSE SUSPENSION ORDERS IN KARNATAKA AND ANDHRA PRADESH

Source text: ID:nNSE5v2zb3

Further company coverage: MEDP.NS

(([email protected];))

June 24 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - OPTIVAL HEALTH SOLUTIONS RECEIVES TWO DRUG LICENSE SUSPENSION ORDERS IN ANDHRA PRADESH

Source text: ID:nBSE8lhGXk

Further company coverage: MEDP.NS

(([email protected];))

** Shares of India's MedPlus Health Services MEDP.NS jump as much as 12.2% to 1,022.20 rupees; last up 7.4%

** Pharmacy chain's Q4 net profit rose 24.6% y/y to 639.8 million rupees ($6.65 million)

** Revenue from ops rose 23.5% y/y, driven by store expansion and strong same-store growth

** Co adds 218 net stores in the quarter, compared with 100 a year earlier

** Consol operating EBITDA margin increased to 5.8% from 5.3% a year earlier

** Trading vols at 9.7x the 30-day average

** MEDP rated "strong buy" on average by seven analysts, median PT: 1,110 rupees - LSEG data

** YTD, stock up ~22.2%

($1 = 96.2200 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

April 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - RECEIVES TWO STAY ORDERS AGAINST SUSPENSION FROM AUTHORITIES IN PUNE, MAHARASHTRA

Source text: ID:nNSE4ncYj7

Further company coverage: MEDP.NS

(([email protected];))

April 20 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVES TWO DRUG LICENSE SUSPENSION ORDERS FOR STORES

Source text: ID:nBSE8yGHmT

Further company coverage: MEDP.NS

(([email protected];))

** Shares of Medplus Health Services MEDP.NS fall 4.8% to 874 rupees

** Stock marks steepest intraday pct loss since January 14

** Nomura maintains "buy" rating; cuts price target to 1,030 rupees from 1,050 rupees

** New PT implies 12.1% upside to last close, compared to previous PT's 14.2% upside

** Says Q1 results missed estimates due to higher employee expenses

** Brokerage lowers fiscal 2026 and 2027 operating EBITDA estimates by ~15%/22%, factoring in slower revenue growth and elevated overheads

** MEDP rated "strong buy" by six analysts on average; median target price is 1,087.5 rupees – data compiled by LSEG

** Stock up 5.2% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

Feb 19 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• STAY ORDER GRANTED AGAINST DEMAND OF 18.9 MILLION RUPEES

Source text: ID:nBSE2P9g0R

Further company coverage: MEDP.NS

(([email protected];;))

Jan 31 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES Q3 CONSOL NET PROFIT 458.9 MILLION RUPEES

• MEDPLUS HEALTH SERVICES Q3 CONSOL REVENUE FROM OPERATIONS 15.61 BILLION RUPEES

Source text: ID:nBSE99Lj0Q

Further company coverage: MEDP.NS

(([email protected];;))

Jan 7 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• OPTIVAL HEALTH SOLUTIONS RECEIVES DRUG LICENSE SUSPENSION ORDER

Source text: ID:nBSE2nPfJT

Further company coverage: MEDP.NS

(([email protected];;))

** Shares of MedPlus Health Services MEDP.NS fall as much as 4.3% to 811 rupees before recovering slightly; last down 3.8%

** Co's unit Optival Health Solutions gets suspension order of drug license for stores in Karnataka and Maharashtra

** Stock on track for second-sharpest intraday fall in 2024

** Avg rating of six analysts is a "strong buy" and median PT is 915 rupees, ~12% higher than current price - LSEG data

** Stock trims YTD gains to around 9%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Dec 19 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - OPTIVAL HEALTH SOLUTIONS RECEIVES DRUG LICENSE SUSPENSION ORDER

Source text: ID:nBSE9dL6xb

Further company coverage: MEDP.NS

(([email protected];))

Nov 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT GOT ONE SUSPENSION ORDER OF DRUG LICENSE FOR FOUR DAYS AT ONE STORE

• MEDPLUS HEALTH SERVICES - POTENTIAL REVENUE LOSS OF 250,000 RUPEES FROM ORDER

Source text: ID:nNSE15b7k9

Further company coverage: MEDP.NS

(([email protected];))

Nov 18 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• PI OPPORTUNITIES FUND-I SOLD 6.9 MILLION SHARES OF MEDPLUS HEALTH SERVICES AT 700 RUPEESPER SHARE VIA BULK DEAL - EXCHANGE DATA

• SBI MUTUAL FUND SOLD 1 MILLION SHARES OF MEDPLUS HEALTH SERVICES AT 700 RUPEESPER SHARE VIA BULK DEAL - EXCHANGE DATA

Source text: [ID:]

Further company coverage: MEDP.NS

(([email protected];;))

** Shares of MedPlus Health Services MEDP.NS rise as much as 7.4% to 724.95 rupees

** MEDP on Tuesday reported its Q2 consol net profit to more than doubled to 387.4 mln rupees ($4.6 mln); rev from ops rose ~12% Y/Y

** Co's retail business, which accounts for nearly all of its revenue, rose 11.3% Y/Y

** More than 1.5 mln shares change hands, 6.5x of 30-day avg

** Avg rating of six analysts equivalent to "strong buy", median PT is 840 rupees - LSEG data

** Stock down 6.5% YTD

($1 = 84.4000 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Nov 12 (Reuters) - India's MedPlus Health Services MEDP.NS reported a sharp jump in second-quarter profit on Tuesday, propelled by strong demand for over-the-counter (OTC) medicines.

The company reported consolidated net profit of 387.4 million rupees ($4.6 million) for the quarter ended Sept. 30, compared to 145.6 million rupees a year ago.

Its revenue from operations rose 12% to 15.76 billion rupees, led by an about 11% jump in its retail business, which accounts for nearly all of its total revenue.

The company did not specify the sales break-up of over-the-counter and prescription medicines, both of which are part of the retail business.

Drugmakers Mankind Pharma's MNKI.NS and Cipla's CIPL.NS domestic revenues were boosted by strong demand for OTC medications, the companies said in their second-quarter earnings statements.

MedPlus Health said in September that it plans to increase its presence in tier-2 cities by opening 600 new stores over the next three years.

The company currently has more than 4,000 outlets in the country, just behind Apollo Pharmacy, which has more than 6,000 stores.

It also said it is focussing on increasing the scalability of products under its own private label in both pharmaceuticals and consumer wellness categories, which according to analysts contributes more to its margins.

MedPlus competes with Reliance Industries' RELI.NS Netmeds and Apollo Pharmacies, both of which are unlisted, among other retail pharmacies in the Indian OTC drug retail market.

($1 = 84.3670 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru and Varun H K)

(([email protected]; 8800437922;))

Oct 31 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED FIVE SUSPENSION ORDERS OF DRUG LICENSE

Source text: ID:nBSEc5fS70

Further company coverage: MEDP.NS

(([email protected];;))

Aug 20 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVED TWO SUSPENSION ORDERS OF DRUG LICENSE

Source text for Eikon: ID:nNSE5Vk96x

Further company coverage: MEDP.NS

(([email protected];))

Aug 2 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES Q1 CONSOL NET PROFIT 143.6 MILLION RUPEES

• MEDPLUS HEALTH SERVICES Q1 CONSOL REVENUE FROM OPERATIONS 14.89 BILLION RUPEESS

Source text for Eikon: ID:nBSE1XHvFg

Further company coverage: MEDP.NS

(([email protected];))

July 24 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT GOT 3 DAYS SUSPENSION ORDER FOR TRICHY STORE

Further company coverage: MEDP.NS

(([email protected];))